Comparison of effects of azilsartan and olmesartan in paitents with type 2 diabetes mellitus with hypertension: A crossover trial.
Not Applicable
- Conditions
- Patients with type 2 diabetes mellitus with hypertension
- Registration Number
- JPRN-UMIN000012619
- Lead Sponsor
- Juntendo University Graduate School of Medicine,Department of Metabolism & Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
1)Pregnant, lactating, and possibly pregnant women 2)severe liver disease 3)severe kidney disease(s-Cr 2.0mg/dl and mora) 4) Treatment with insurin 5) patients who have allergy to the medicine used in this study 6)Patients attending physician has determined is inappropriate for research participation 7)Patients who do not obtain written consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Office blood pressure
- Secondary Outcome Measures
Name Time Method 24hour blood pressure,daytime blood pressure,night time blood pressure(ABPM at 16,48weeks),HbA1c, FBG, IRI, urinary microalbumin, glucosylated albumin, hs-CRP, adiponectin, L-FABP, pentraxin3
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate azilsartan and olmesartan in blood pressure regulation for type 2 diabetes patients with hypertension?
How does azilsartan compare to olmesartan in terms of renal protective effects in JPRN-UMIN000012619 crossover trial for T2DM hypertension?
Which biomarkers correlate with improved glycemic control or reduced cardiovascular risk in T2DM patients treated with azilsartan versus olmesartan?
What are the safety profiles of azilsartan and olmesartan in patients with type 2 diabetes and hypertension, including hyperkalemia or renal dysfunction risks?
How does the JPRN-UMIN000012619 trial evaluate azilsartan and olmesartan against other ARBs or combination therapies for T2DM-related hypertension?